Modality
Radioligand
MOA
WEE1i
Target
CDK2
Pathway
Apoptosis
RBWilms
Development Pipeline
Preclinical
~May 2022
→ ~Aug 2023
Phase 1
Nov 2023
→ Sep 2030
Phase 1Current
NCT03741949
2,831 pts·RB
2023-11→2030-09·Not yet recruiting
2,831 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-09-024.4y awayInterim· RB
Trial Timeline
Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1
Not yet…
Catalysts
Interim
2030-09-02 · 4.4y away
RB
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03741949 | Phase 1 | RB | Not yet recr... | 2831 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 | |
| AMG-415 | Amgen | Phase 1 | CDK2 | |
| AMG-9052 | Amgen | Phase 2/3 | CDK2 | |
| Zanuratamab | Gilead Sciences | Phase 1/2 | CDK2 |